Background: Oxytocin is generally used in obstetric exercise as a uterotonic drug for induction and augmentation of labor and stays the drug of desire for facilitating uterine contractions all through vaginal and operative delivery. It is now spreading up to far-flung areas. The infusion method of oxytocin is protected in the caesarean area beneath spinal anaesthesia. Objective: This is to evaluate the hemodynamic modifications precipitated by oxytocin given as an I/V bolus or infusion to limit uterine bleeding in cesarean section. Methods: This prospective, interventional learning was once carried out at the Department of Anaesthesiology, Abdul Malek Ukil Medical College & Hospital, Noakhali, Bangladesh, from January to December 2020. A whole range of fifty sufferers ASA grade I had been selected. Thirty affected people in every group. In crew A, the parturient acquired oxytocin 5IU of I/V in bolus, and in team B, infusion of oxytocin 5IU diluted with 5ml everyday saline given I/V over two min by way of the use of infusion pump. Systolic and diastolic BP, MAP, coronary heart rate, uterine bleeding have been recorded every 1 min. The learning about duration used to be started out simply earlier than oxytocin is given, and it used to be persisted for an additional 10 min. Results: In our study, every group had n=25. All outcomes are expressed as mean± standard deviation. The studied groups became statistically matched for age, gestational age, weight, coronary heart rate, systolic and diastolic blood pressure, suggesting arterial pressure. The implied distinction of all hemodynamic parameters at 2 to 5 minutes of oxytocin administration has been statistically significant (p<0.05). Conclusion: Oxytocin remains the first-line uterotonic after vaginal and caesarean delivery. The hemodynamic changes were more marked in the I/V bolus of oxytocin than infusion technique. Recent research elucidates the therapeutic range of oxytocin during caesarean delivery and receptor desensitization. A slower injection of oxytocin can effectively minimize cardiovascular side effects and equally effectively reduce blood loss without compromising the therapeutic benefits. Evidence-based protocols for preventing and treating uterine atony during cesarean delivery are recommended.